HDAC9 and central nervous system cancer: Although extensive research has been performed on HDACi in glioma with clear radio- and/or chemosensitizing effects, the potential of radiolabeled HDACi has only been confirmed in the field of neurodegenerative diseases and been primarily diagnostic, with the goal of quantifying HDAC expression and/or monitoring treatment response.